Utility of ACMG classification to support interpretation of molecular genetic test results in patients with factor VII deficiency.

Autor:	Alesci RS; IMD Blood Coagulation Centre, Bad Homburg, Germany., Hecking C; IMD Blood Coagulation Centre, Bad Homburg, Germany., Racké B; Institute of Immunology and Genetics, Kaiserslautern, Germany., Janssen D; Med-i-Scene Concept, Weisendorf, Germany., Dempfle CE; IMD Blood Coagulation Centre, Mannheim, Germany.
Jazyk:	angličtina
Zdroj:	Frontiers in medicine [Front Med (Lausanne)] 2023 Jul 14; Vol. 10, pp. 1220813. Date of Electronic Publication: 2023 Jul 14 (Print Publication: 2023).
DOI:	10.3389/fmed.2023.1220813
Abstrakt:	Background: The American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) have introduced an internationally shared framework for variant classification in genetic disorders. FVII deficiency is a rare inherited autosomal recessive bleeding disorder with sparse data concerning ACMG classification. Methods: To develop an approach which may improve the utility of molecular genetic test results, 129 patients with FVII deficiency were retrospectively assigned to six subgroups for exploratory analysis: F7 gene wildtype (group 1) , ACMG 1 (benign variant) or ACMG 2 (likely benign variant), only (group 2) , ACMG 3 (variant of uncertain significance) ± ACMG 1-2 heterozygous or not classified variant (group 3) , ACMG 4 (likely pathogenic variant), or ACMG 5 (pathogenic variant) single heterozygous ± ACMG 1-3 single heterozygous (group 4) , ACMG 4-5 homozygous or ≥2 ACMG 4-5 heterozygous or ≥1 ACMG 4-5 heterozygous plus either ACMG 1 c.1238G>A modifying variant homozygous or ≥2 ACMG 1-3 (group 5) , FVII deficiency and another bleeding disorder (group 6) . Results: Eleven of 31 patients (35.5%) in group 5 had abnormal ISTH-BS ( n = 7) and/or history of substitution with recombinant factor VIIa ( n = 5) versus 4 of 80 patients (5.0%, n = 1 abnormal ISTH-BS, n = 3 substitution) in groups 1 ( n = 2/22), 2 ( n = 1/29), 3 ( n = 0/9), and 4 ( n = 1/20). Four of 18 patients (22.2%) with FVII deficiency and another bleeding disorder (group 6) had an abnormal ISTH-BS ( n = 2) and/or history of substitution with recombinant factor VIIa ( n = 3). Conclusion: Patients with a homozygous ACMG 4-5 variant or with specific combinations of heterozygous ACMG 4-5 ± ACMG 1-3 variants exhibited a high-risk bleeding phenotype in contrast to the remaining patients without another bleeding disorder. This result may serve as a basis to develop a genotype/phenotype prediction model in future studies. Competing Interests: DJ is the owner of Med-i-Scene Concept GmbH, Weisendorf, Germany, which received the funding for this study from Novo Nordisk Pharma GmbH, Mainz, Germany, in conjunction with an existing basic agreement for scientific services. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor FS declared a past co-authorship with the author RA. (Copyright © 2023 Alesci, Hecking, Racké, Janssen and Dempfle.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu